Business, energy, technology, markets and global industry news from Business News Today

epilepsy

PharmaDeviceNews epilepsy
Representative image: Angelini Pharma’s $4.1 billion Catalyst Pharmaceuticals acquisition highlights the growing race for rare disease and neurology assets, with Firdapse, Agamree and U.S. commercial scale at the center of the deal.
Pharma & Biotech

Angelini Pharma bets $4.1bn on rare neurology scale with Catalyst Pharmaceuticals

Angelini gains U.S. rare disease scale. Catalyst gets certainty, but Firdapse concentration keeps the real test ahead.

Read More
Representative image depicting the neurological basis of amyotrophic lateral sclerosis (ALS), highlighting motor neuron degeneration and cortical hyperexcitability. This visual supports our coverage of QurAlis’ Kv7.2/7.3-targeted therapy QRL-101 and its implications in ALS drug development.
Pharma & Biotech

QurAlis links QRL-101 to motor nerve excitability shift in ALS: Is target validation finally here?

QurAlis confirms target engagement of QRL-101 in ALS patients. Find out what this means for epilepsy trials and Kv7-targeted drug development.

Read More
Representative image depicting neuropharmaceutical research and CNS drug development, relevant to Biohaven’s focus on Kv7 modulation and epilepsy pipeline after its BHV-7000 depression trial results.
Pharma & Biotech

Biohaven ends psychiatric push for BHV-7000 after Phase 2 trial in depression fails to show efficacy

Biohaven Ltd. has reported that BHV-7000, its experimental Kv7 ion channel modulator, failed to meet the primary endpoint in a Phase 2 proof-of-concept trial evaluating the drug in patients with major depressive disorder. The trial assessed changes in depressive symptoms using the Montgomery-Åsberg Depression Rating Scale over six weeks compared to placebo. Although some numerical

Read More